Gastric cancer+3
RecruitingStudy of HLX22, Trastuzumab, and Chemotherapy for Patients with Advanced or Metastatic Stomach and Gastroesophageal Cancer
Study of HLX22, Trastuzumab, and Chemotherapy for Patients with Advanced or Metastatic Stomach and Gastroesophageal Cancer
- Disease:Gastric cancerOesophageal carcinoma+2
- Substances:PembrolizumabHUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2
Poland- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
- Sponsor:Shanghai Henlius Biotech Inc.











